Here's how the ASX 200 market sectors stacked up last week

Healthcare was the strongest sector last week, with market darling Pro Medicus surging yet again.

Medical or healthcare workers grasp hands in the universal expression of teamwork

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

ASX 200 healthcare shares led the market sectors with a 1.15% increase over the five trading days.

The S&P/ASX 200 Index (ASX: XJO) gained 0.53% over the week to finish at 8,294.1 points on Friday.

Seven of the 11 market sectors finished the week in the green.

Let's review the week's events.

Healthcare shares led the ASX sectors last week

Among the healthcare sector heavyweights, CSL Ltd (ASX: CSL) shares lifted 0.59% to $285.09.

Pro Medicus Ltd (ASX: PME) shares rose 5.92% despite no price-sensitive news last week.

Pro Medicus continues to ride a positive wave of momentum after delivering the best share price growth among the ASX 200 large-cap shares last year.

Resmed CDI (ASX: RMD) shares lifted 2.72% to $37.76 per share. Resmed announced it will reveal its second-quarter results on 30 January.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares lifted 0.35% to $34.30 apiece.

The Cochlear Ltd (ASX: COH) share price rose 0.92% to $301.20.

Shares in pathology provider Sonic Healthcare Ltd (ASX: SHL) lifted 1.56% to close at $27.99 on Friday.

Telix Pharmaceuticals Ltd (ASX: TLX) shares ascended 0.63% to $23.99.

Other strong performers last week include Sigma Healthcare Ltd (ASX: SIG) shares, which gained 7.91% and hit an almost two-decade high of $3.05 on Friday. The Sigma share price closed the week at $3.

Last week, the Amcal chemist owner did not provide any news, as excited investors awaited the conclusion of its merger with Chemist Warehouse.

Among the fallers last week were Clarity Pharmaceuticals Ltd (ASX: CU6) shares, which lost 5.61% in value to close at $3.87 on Friday.

Mesoblast Ltd (ASX: MSB) shares lost 11.36% between Monday and Thursday before going into a trading halt prior to Friday's market open.

The company intends to make an announcement about a "proposed financing" shortly.

For now, the Mesoblast share price is frozen at $2.81. The ASX biotech asked for the trading halt to remain in place until the time of the announcement or the commencement of trading on Tuesday.

Mesoblast shares are still up a whopping 65% despite last week's share price correction.

Investors have been buying Mesoblast shares after the company finally gained approval from the United States Food and Drug Administration for its lead drug, remestemcel-L, last month.

Stock in private healthcare provider and hospital owner Ramsay Health Care Ltd (ASX: RHC) also fell last week. The Ramsay share price lost 2.48% to finish the week at $33.75 per share.

ASX 200 market sector snapshot

Here's how the 11 market sectors stacked up last week, according to CommSec data.

Over the five trading days:

S&P/ASX 200 market sectorChange last week
Healthcare (ASX: XHJ) 1.15%
Financials (ASX: XFJ)0.83%
Information Technology (ASX: XIJ)0.76%
Consumer Discretionary (ASX: XDJ)0.74%
Materials (ASX: XMJ)0.71%
A-REIT (ASX: XPJ)0.42%
Utilities (ASX: XUJ)0.02%
Communication (ASX: XTJ)(0.21%)
Industrials (ASX: XNJ) (0.31%)
Energy (ASX: XEJ)(0.49%)
Consumer Staples (ASX: XSJ) (1.56%)

Motley Fool contributor Bronwyn Allen has positions in CSL and Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL, Cochlear, Pro Medicus, Sonic Healthcare, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »